GKOS – Glaukos Corporation

Glaukos Corporation

GKOS

$101.42

Name : Glaukos Corporation

Sector : Healthcare

Industry: Medical Devices

Mark. Cap: $5,795,189,248.00

EPSttm : -2.27

Glaukos Corporation

$101.42

0.36%

$0.36

Float Short %

7.24

Margin Of Safety %

Put/Call OI Ratio

0.26

EPS Next Q Diff

-0.01

EPS Last/This Y

1.91

EPS This/Next Y

0.9

Price

101.54

Target Price

122.46

Analyst Recom

1.62

Performance Q

-2.12

Relative Volume

1.96

Beta

0.81

Ticker: GKOS

19 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-06-02	GKOS	94.86	0.34	0.00	2819
2025-06-03	GKOS	94.46	0.37	0.04	2641
2025-06-04	GKOS	90.96	0.35	0.50	2744
2025-06-05	GKOS	92.65	0.35	0.18	2749
2025-06-06	GKOS	92.96	0.34	57.43	2800
2025-06-09	GKOS	94.64	0.72	0.50	3617
2025-06-10	GKOS	95.65	0.72	0.06	3623
2025-06-11	GKOS	99.18	0.71	0.01	3653
2025-06-12	GKOS	97.61	0.45	0.85	4972
2025-06-13	GKOS	97.61	0.46	0.26	4989
2025-06-16	GKOS	100.21	0.45	0.07	5057
2025-06-17	GKOS	99.93	0.45	0.07	5084
2025-06-18	GKOS	102.3	0.45	1.24	5123
2025-06-20	GKOS	100.09	0.46	0.39	5184
2025-06-23	GKOS	96.82	0.26	0.49	2906
2025-06-24	GKOS	100.22	0.27	0.33	2918
2025-06-25	GKOS	99.38	0.26	0.00	2920
2025-06-26	GKOS	101.06	0.26	0.07	2920
2025-06-27	GKOS	101.51	0.26	0.13	2926
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-06-02	GKOS	94.80	49.3	41.2	-0.86
2025-06-03	GKOS	94.49	49.3	41.9	-0.86
2025-06-04	GKOS	90.96	49.3	44.5	-0.86
2025-06-05	GKOS	92.69	49.3	40.2	-0.86
2025-06-06	GKOS	92.97	49.3	41.4	-0.86
2025-06-09	GKOS	94.64	49.3	40.3	-0.86
2025-06-10	GKOS	95.65	49.3	40.8	-0.86
2025-06-11	GKOS	99.18	49.3	38.8	-0.86
2025-06-12	GKOS	97.60	49.3	42.8	-0.86
2025-06-13	GKOS	97.72	49.3	41.5	-0.86
2025-06-16	GKOS	100.24	49.3	39.6	-0.86
2025-06-17	GKOS	99.88	49.3	41.8	-0.86
2025-06-18	GKOS	102.34	49.3	39.7	-0.86
2025-06-20	GKOS	100.15	49.3	43.3	-0.86
2025-06-23	GKOS	96.79	49.3	44.2	-0.86
2025-06-24	GKOS	100.21	49.3	38.9	-0.86
2025-06-25	GKOS	99.31	49.3	42.3	-0.86
2025-06-26	GKOS	101.09	49.3	40.3	-0.86
2025-06-27	GKOS	101.54	49.3	41.3	-0.86
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-06-02	GKOS	-1.91	0.47	6.09
2025-06-03	GKOS	-1.91	0.47	6.09
2025-06-04	GKOS	-1.91	0.47	6.09
2025-06-05	GKOS	-1.91	0.47	6.09
2025-06-06	GKOS	-1.91	0.47	6.09
2025-06-09	GKOS	-1.91	0.40	6.09
2025-06-10	GKOS	-1.93	0.40	6.09
2025-06-11	GKOS	-1.93	0.40	6.99
2025-06-12	GKOS	-1.93	0.40	6.99
2025-06-13	GKOS	-1.93	0.40	6.99
2025-06-16	GKOS	-1.83	0.40	6.99
2025-06-17	GKOS	-1.83	0.40	6.99
2025-06-18	GKOS	-1.83	0.40	6.99
2025-06-20	GKOS	-1.83	0.40	7.00
2025-06-23	GKOS	-1.78	0.40	7.00
2025-06-24	GKOS	-1.18	0.40	7.00
2025-06-25	GKOS	-1.18	0.40	7.00
2025-06-26	GKOS	-1.18	0.40	7.24
2025-06-27	GKOS	-1.18	0.40	7.24
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-0.22

Avg. EPS Est. Current Quarter

-0.26

Avg. EPS Est. Next Quarter

-0.23

Insider Transactions

-1.18

Institutional Transactions

0.4

Beta

0.81

Average Sales Estimate Current Quarter

115

Average Sales Estimate Next Quarter

120

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-64.3

Target Price

122.46

P/E

Forward P/E

3199.37

PEG

P/S

14.33

P/B

7.53

P/Free Cash Flow

EPS

-2.31

Average EPS Est. Cur. Y

-0.86

EPS Next Y. (Est.)

0.03

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-30.57

Relative Volume

1.96

Return on Equity vs Sector %

-40.1

Return on Equity vs Industry %

-34.6

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

41.3

Glaukos Corporation

Sector: Healthcare

Industry: Medical Devices

Employees: 995

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The company offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. It also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension; iAccess, a precision blade; and iPRIME, a viscoelastic delivery system. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

stock quote shares GKOS – Glaukos Corporation Stock Price stock today

news today GKOS – Glaukos Corporation stock forecast ,stock prediction 2023 2024 2025

marketwatch GKOS – Glaukos Corporation yahoo finance google finance

stock history GKOS – Glaukos Corporation invest stock market

stock prices GKOS premarket after hours

ticker GKOS fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

GKOS – Glaukos Corporation

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: GKOS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y